NeuroGenomeX, Inc.

Company News

NeuroGenomeX, Inc. and Wisconsin Alumni Research Foundation Announce Licensing Agreement

April 2004, Madison, WI -- The Wisconsin Alumni Research Foundation (WARF) and NeuroGenomeX, Inc. announced today that they had signed a license agreement giving NeuroGenomeX exclusive rights to develop 2-deoxy-D-glucose (2DG) for the treatment of neurological disorders, including epilepsy. 2DGs use as an anti-epileptic agent was developed in the laboratory of Dr. Thomas Sutula, Chairman of the Department of Neurology at the University of Wisconsin-Madison. WARF is the sole patenting and licensing arm of the UW-Madison.

‹- Back